What are biomolecular condensates, how are they opening new frontiers in drug discovery, and what tools make this possible? Elie Dolgin explains in the pages of Nature. https://lnkd.in/e9HmNufw
Nereid Therapeutics
Biotechnology
Boston , MA 1,805 followers
Translating the therapeutic promise of biomolecular condensates -- from physics to physicians
Über uns
Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and resulting biomolecular condensates. Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases. For more information, visit www.nereidtx.com.
- Website
-
https://www.nereidtx.com
External link for Nereid Therapeutics
- Industrie
- Biotechnology
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Boston , MA
- Typ
- In Privatbesitz
- Gegründet
- 2020
Standorte
-
Primäre
Boston , MA, US
Employees at Nereid Therapeutics
-
Ivan Efremov
VP, Head of Chemistry at Nereid Therapeutics
-
Matt Jacobson
Biotech Entrepreneur and UCSF Professor
-
Vincent Huber
Drug discovery researcher located in Fujisawa Japan
-
Michael Kauffman
CEO & President, Nereid Therapeutics; Drug Developer, Board Member, Physician Scientist
Aktualisierungen
-
We are thrilled to welcome Michael Kauffman to Nereid as our new President and Chief Executive Officer! https://lnkd.in/ewxhJCqG
Nereid Therapeutics Appoints Michael Kauffman as CEO
prnewswire.com